Curriculum Vitae

Prof. Dr. CHRISTOS Ν. YAPIJAKIS, B.S., M.S., D.M.D., Ph.D.
Medical Geneticist – Clinical and Molecular Geneticist

CURRENT POSITIONS
•Assistant Professor of Biology-Neurogenetics
Department of Neurology, University of Athens Medical School, Eginition Hospital,
Vas. Sofias 72, Athens GR-11528, Greece
•Director
Cephalogenetics Diagnostic Center, Filaretou 88, Kallithea, Athens GR-17672, Greece
Telephone: +30-210-9595772 +30-6932 263732 Email cyapi@med.uoa.gr

EDUCATION
Basic Studies:
•Diploma in Biology (University of Athens, School of Basic Sciences)
•Diploma in Dental Medicine (University of Athens, School of Health Sciences)

Graduate Studies:
•Master in Molecular Biology (University of California School of Biology, Santa Cruz, USA)
•Doctorate Thesis in Medical Genetics (University of Athens of Basic Sciences) with the title: “Molecular genetic study of Huntington disease and myotonic family in Greek families” (Supervisor: Professor Dimitris Loukopoulos,MD,PhD)

PROFESSIONAL TITLES
•Certificate in Medical Genetics (International School of Medical Genetics, Italy)
•Licence in Dental Surgery (Greece)
•European Professional Biologist Title (European Union)

SCHOLARSHIPS
•University of Athens (during studies for the Diploma in Biology)
•University of California (Tuition waiving and Teaching assistant double scholarship during Master studies)
•Greek State Institution of Scholarships (during Doctorate research)
•United Nations Center of Genetic Engineering and Biotechnology (for the attendance of the International School of Medical Genetics)
•European Science Foundation Postdoctoral Scholarship in Neuroscience (for a european collaborative research project)

RESEARCH WORK
Research Fields:
Neurogenetics, Genetics of Head and Neck Syndromes, Molecular Oncology
Research Facilities:
At the University of Athens Medical School:
•1st Department of Internal Medicine (Doctorate Candidate 1989-1993)
•Department of Neurology (Major Contributor in establishing Laboratory of Clinical and Molecular Neurogenetics in 1993 and Lab Supervisor 1993-2003 – Researcher in Neurobiology Unit 2003-present)
•Department of Oral and Maxillofacial Surgery (Major Contributor in establishing Laboratory of Molecular Biology in 2004 and Lab Supervisor 2004-present) As Visiting Associate Researcher:
•In USA: University of California (Santa Cruz), Mount Sinai Medical School (NYC), Johns Hopkins Medical School (Baltimore).
•In European Centers of Medical Genetics in UK (Cardiff), in Italy (Torino), in Belgium (Antwerpen) and in Cyprus (Nicosia). Research Distinctions:
•1st Basic Science Prize in World Congress of Oral Oncology: «Role of oncogenes and tumour suppressor genes in sequential stages of oral oncogenesis in an experimental animal model» (2007)
•1st Prize in European Conference of Neurology: “Clinical, immunological and genetic parameters in two patients with spinal and bulbar muscular atrophy” (1997)
•1st Prize in 22nd Panhellenic Conference of Endocrinology: “Point mutations in ret oncogene in patients with MEN2A syndrome” (1995)
•Prize “Symvoulidion” (for personal research and a review monograph) in the 24th Panhellenic Conference of Medicine: “Neurodegenerative disorders caused by trinucleotide repeats” (1998)
•1st Prize in 28th Panhellenic Conference of Endocrinology: “Association study of DNA polymorphisms in genes of estrogen receptor and androgen receptor with male infertility” (2001) Participation in Funded Research Programs:
•3 European (BIOMED)
•8 Greek (PENED – Pythagoras)

MEMBER OF SCIENTIFIC SOCIETIES International Societies:
•European Society of Human Genetics (since 1990) – Board Member (2002-2007)
•European Countries Biologists Association – Board Member (1993-99)
•American Association for the Advancement of Science
•Federation of American Scientists
•International Association of Greek Neuroscientists
•Biopolitics International Organization
•and 4 others

Greek Societies:
•Panhellenic Union of Biologists/Bioscientists – President (1993-95,1995-97,1997-99)
•Hellenic Association of Medical Geneticists – Board Member (2001-03, 2003-05, 2007-2009)
•Greek Society of Medical Molecular Biologists – Vice President (2001-05)
•Greek Neurological Society – Member of Publications Committee (2003-07)
•and 6 others

SCIENTIFIC PUBLICATIONS
Total International Publications: 139 (Cited in >800 works of other authors)
•95 in International Journals with Referrees (87 MedLine – Impact factor >200)
•11 Chapters in International Books
•52 Presentations in International Conferences

Total Greek Publications: 76
•18 in Greek Scientific Journals
•8 Chapters in University Books
•59 Presentations in Greek Conferences

EPISTEMOLOGICAL/PHILOSOPHICAL PUBLICATIONS
•1 Book
•1 Paper in English
•27 Essays in Greek

PUBMED PUBLICATIONS
1. Cerebrovascular Aneurysms May Be Associated with Thrombophilia-predisposing Mutations in Patients with Familial Risk. Andreou A, Papapetrou C, Papadimitriou K, Avgoustidis D, Yapijakis C. In Vivo. 2015 05-06;29(3):395-398.

2. Juvenile myoclonic epilepsy is not associated with the DRPLA gene in a European population. Yapijakis C, Gatzonis S, Youroukos S, Kollia V, Karachristianou S, Anagnostouli M. In Vivo. 2014 Nov-Dec;28(6):1193-6.

3. High frequency of TTTY2-like gene-related deletions in patients with idiopathic oligozoospermia and azoospermia. Yapijakis C, Serefoglou Z, Papadimitriou K, Makrinou E. Andrologia. 2015 Jun;47(5):536-44.

4. Effect of Thrombosis-related Gene Polymorphisms upon Oral Cancer: A Regression Analysis. Vylliotis A, Yapijakis C, Nkenke E, Nisyrios T, Avgoustidis D, Adamopoulou M, Ragos V, Vassiliou S, Koronellos N, Vairaktaris E. Anticancer Res. 2013 Sep;33(9):4033-9.

5. Prevalence of human papillomavirus in saliva and cervix of sexually active women. Adamopoulou M, Vairaktaris E, Nkenke E, Avgoustidis D, Karakitsos P, Sioulas V, Nisyrios T, Yapijakis C. Gynecol Oncol. 2013 May;129(2):395-400. doi: 10.1016/j.ygyno.2013.02.015. Epub 2013 Feb 18.

6. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma. Yapijakis C, Koronellos N, Spyridonidou S, Vylliotis A, Avgoustidis D, Goutas N, Vlachodimitropoulos D, Vairaktaris E. Arch Dermatol Res. 2013 May;305(4):333-9.

7. Prevalence of thrombosis-related DNA polymorphisms in a healthy Greek population. Yapijakis C, Serefoglou Z, Nixon AM, Vylliotis A, Ragos V, Vairaktaris E. In Vivo. 2012 Nov-Dec;26(6):1095-101.

8. Oral carcinogenesis is not achieved in different carcinogen-treated PAI-1 transgenic and wild-type mouse models. Avgoustidis D, Nisyrios T, Nkenke E, Lijnen R, Ragos V, Perrea D, Donta I, Vaena A, Yapijakis C, Vairaktaris E. In Vivo. 2012 Nov-Dec;26(6):1001-5.

9. The interplay between hemostasis and malignancy: the oral cancer paradigm. Yapijakis C, Bramos A, Nixon AM, Ragos V, Vairaktaris E. Anticancer Res. 2012 May;32(5):1791-800.

10. Potential prevention of thromboembolism by genetic counseling and testing for two common thrombophilia mutations. Yapijakis C, Antoniadi T, Salavoura K, Voumvourakis C, Vairaktaris E. In Vivo. 2012 Jan-Feb;26(1):165-72.

11. Homocysteinemia-associated anetoderma, in a young woman with anorexia nervosa history. Aroni K, Ioannidis E, Voudouris S, Yapijakis C. Int J Dermatol. 2011 Mar;50(3):343-5.

12. Bisphosphonate-induced avascular osteonecrosis of the mandible associated with a common thrombophilic mutation in the prothrombin gene. Vairaktaris E, Vassiliou S, Avgoustidis D, Stathopoulos P, Toyoshima T, Yapijakis C. J Oral Maxillofac Surg. 2009 Sep;67(9):2009-12.

13. Comparison of cytology, colposcopy, HPV typing and biomarker analysis in cervical neoplasia. Adamopoulou M, Kalkani E, Charvalos E, Avgoustidis D, Haidopoulos D, Yapijakis C. Anticancer Res. 2009 Aug;29(8):3401-9.

14. A common 9 bp deletion in the ataxia-telangiectasia-mutated gene is not associated with oral cancer. Spyridonidou S, Yapijakis C, Nkenke E, Toyoshima T, Vylliotis A, Serefoglou Z, Neukam FW, Patsouris E, Vairaktaris E. Anticancer Res. 2009 Aug;29(8):3191-3.

15. Hippocrates of kos, the father of clinical medicine, and asclepiades of bithynia, the father of molecular medicine. Review. Yapijakis C. In Vivo. 2009 Jul-Aug;23(4):507-14.

16. Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer.Yapijakis C, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW, Patsouris E, Vairaktaris E. Anticancer Res. 2009 Jun;29(6):2379-86.

17. Screening for Familial Mediterranean Fever M694V and V726A mutations in the Greek population. Gkretsi V, Deltas C, Yapijakis C, Lamnissou K. Genet Test Mol Biomarkers. 2009 Jun;13(3):291-3.

18. Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation. Vairaktaris E, Goutzanis L, Yapijakis C, Vassiliou S, Spyridonidou S, Vylliotis A, Nkenke E, Lazaris AC, Strantzias P, Patsouris E. Histol Histopathol. 2009 May;24(5):531-9.

19. Association of leptin -2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer. Yapijakis C, Kechagiadakis M, Nkenke E, Serefoglou Z, Avgoustidis D, Vylliotis A, Perrea D, Neukam FW, Patsouris E, Vairaktaris E. J Cancer Res Clin Oncol. 2009 Apr;135(4):603-12. Epub 2008 Oct 15.

20. H-ras and c-fos exhibit similar expression patterns during most stages of oral oncogenesis. Vairaktaris E, Papakosta V, Derka S, Vassiliou S, Nkenke E, Spyridonidou S, Vylliotis A, Lazaris A, Kokkori A, Moulavassili P, Loukeri S, Perrea D, Donta I, Yapijakis C, Patsouris E. In Vivo. 2008 Sep-Oct;22(5):621-8.

21. HPV detection rate in saliva may depend on the immune system efficiency. Adamopoulou M, Vairaktaris E, Panis V, Nkenke E, Neukam FW, Yapijakis C. In Vivo. 2008 Sep-Oct;22(5):599-602.

22. Prevalence of HPV types in a cohort of Greeks with clinical indication of infection. Yapijakis C, Adamopoulou M, Antonopoulos G, Koufaliotis N, Vairaktaris E. Anticancer Res. 2008 Jul-Aug;28(4B):2233-7.

23. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, Spyridonidou S, Derka S, Vassiliou S, Nkenke E, Patsouris E. Oral Oncol. 2009 Mar;45(3):247-53.

24. Angiotensinogen polymorphism is associated with risk for malignancy but not for oral cancer. Vairaktaris E, Yapijakis C, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Critselis E, Avgoustidis D, Neukam F, Patsouris E. Anticancer Res. 2008 May-Jun;28(3A):1675-9.

25. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Oral Oncol. 2008 Dec;44(12):1093-9.

26. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Spyridonidou S, Neukam FW, Schlegel KA, Patsouris E. Anticancer Res. 2008 Jan-Feb;28(1A):309-14.

27. A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. Vairaktaris E, Vylliotis A, Spyridonodou S, Derka S, Vassiliou S, Nkenke E, Yapijakis C, Serefoglou Z, Neukam FW, Patsouris E. Anticancer Res. 2008 Jan-Feb;28(1A):271-5.

28. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Patsouris E. J Cancer Res Clin Oncol. 2008 Aug;134(8):821-32.

29. Diabetes and oral oncogenesis. Vairaktaris E, Spyridonidou S, Goutzanis L, Vylliotis A, Lazaris A, Donta I, Perrea D, Yapijakis C, Patsouris E. Anticancer Res. 2007 Nov-Dec;27(6B):4185-93.

30. The platelet glycoprotein Ibalpha VNTR polymorphism is associated with risk for oral cancer. Vairaktaris E, Serefoglou ZC, Yapijakis C, Vassiliou S, Nkenke E, Avgoustidis D, Vylliotis A, Stathopoulos P, Neukam FW, Patsouris E. Anticancer Res. 2007 Nov-Dec;27(6B):4121-5.

31. Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, Serefoglou Z, Vorris E, Vylliotis A, Ragos V, Neukam FW, Patsouris E. Anticancer Res. 2007 Nov-Dec;27(6B):4095-100.

32. A metalloproteinase-13 polymorphism affecting its gene expression is associated with advanced stages of oral cancer. Vairaktaris E, Yapijakis C, Nkenke E, Serefoglou ZC, Chatzitheofylaktou A, Vassiliou S, Derka S, Vylliotis A, Perrea D, Neukam FW, Patsouris E. Anticancer Res. 2007 Nov-Dec;27(6B):4027-30.

33. The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Vairaktaris E, Serefoglou Z, Yapijakis C, Agapi C, Vassiliou S, Nkenke E, Antonis V, Sofia S, Neukam FW, Patsouris E. Anticancer Res. 2007 Nov-Dec;27(6B):4011-4.

34. The interleukin-1 beta gene polymorphism +3953 C/T is not associated with risk for oral cancer. Vairaktaris E, Serefoglou Z, Yapijakis C, Stathopoulos P, Vassiliou S, Derka S, Nkenke E, Vylliotis A, Ragos V, Neukam FW, Patsouris E. Anticancer Res. 2007 Nov-Dec;27(6B):3981-6.

35. The hamster model of sequential oral oncogenesis. Vairaktaris E, Spyridonidou S, Papakosta V, Vylliotis A, Lazaris A, Perrea D, Yapijakis C, Patsouris E. Oral Oncol. 2008 Apr;44(4):315-24. Epub 2007 Dec 3.

36. Increased risk of oral cancer in diabetic animals is not associated with c-jun activation pathway. Vairaktaris E, Goutzanis L, Kalokerinos G, Vassiliou S, Spyridonidou S, Avgoustidis D, Strantzias P, Lazaris A, Papageorgiou G, Ragos V, Yapijakis C, Patsouris E. J Craniomaxillofac Surg. 2007 Dec;35(8):382-7. Epub 2007 Nov 26. 37. Evaluation of apoptosis in nasal and buccal cells of septic patients. Vassiliou S, Yapijakis C, Derka S, Papakosta V, Psyrri A, Antonakis P, Goutzanis L, Konstadoulakis M, Androulakis G, Vairaktaris E. In Vivo. 2007 Sep-Oct;21(5):901-4.

38. EGFR and c-Jun exhibit the same pattern of expression and increase gradually during the progress of oral oncogenesis. Vairaktaris E, Loukeri S, Vassiliou S, Nkenke E, Spyridonidou S, Vylliotis A, Papakosta V, Lazaris A, Agrogiannis G, Yapijakis C, Perrea D, Patsouris E. In Vivo. 2007 Sep-Oct;21(5):791-6.

39. Expression of cell cycle regulator p16 is not affected by diabetes during oral oncogenesis. Vairaktaris E, Goutzanis L, Nkenke E, Spyridonidou S, Vassiliou S, Derka S, Vylliotis A, Yapijakis C, Lazaris A, Patsouris E. In Vivo. 2007 Sep-Oct;21(5):745-50.

40. Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII. Vairaktaris E, Vassiliou S, Yapijakis C, Spyridonidou S, Vylliotis A, Derka S, Nkenke E, Fourtounis G, Neukam FW, Patsouris E. Oncol Rep. 2007 Dec;18(6):1537-43.

41. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer. Vairaktaris E, Yapijakis C, Tsigris C, Vassiliou S, Derka S, Nkenke E, Spyridonidou S, Vylliotis A, Vorris E, Ragos V, Neukam FW, Patsouris E. Acta Oncol. 2007;46(8):1097-102.

42. Diabetes enhances cell proliferation but not Bax/Bcl-2-mediated apoptosis during oral oncogenesis. Vairaktaris E, Kalokerinos G, Goutzanis L, Yapijakis C, Derka S, Vassiliou S, Spyridonidou S, Vylliotis A, Nkenke E, Lazaris A, Patsouris E. Int J Oral Maxillofac Surg. 2008 Jan;37(1):60-5.

43. Diabetes does not influence oral oncogenesis through fibroblast growth factor receptors. Vairaktaris E, Goutzanis L, Nkenke E, Spyridonidou S, Vassiliou S, Derka S, Vylliotis A, Yapijakis C, Lazaris A, Strantzias P, Kalimeras E, Patsouris E. In Vivo. 2007 Jul-Aug;21(4):623-8.

44. Diabetes increases both N-ras and ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential. Vairaktaris E, Goutzanis L, Kalokerinos G, Yannopoulos A, Yapijakis C, Vassiliou S, Spyridonidou S, Vylliotis A, Nkenke E, Lazaris AC, Tesseromatis C, Patsouris E. In Vivo. 2007 Jul-Aug;21(4):615-21.

45. Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats. Vairaktaris E, Goutzanis L, Vassiliou S, Spyridonidou S, Nkenke E, Papageorgiou G, Strantzias P, Lazaris A, Yapijakis C, Patsouris E. J Cancer Res Clin Oncol. 2008 Mar;134(3):337-44.

46. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Vairaktaris E, Serefoglou Z, Yapijakis C, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW, Patsouris E. Anticancer Res. 2007 Jul-Aug;27(4B):2493-8.

47. Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer. Vairaktaris E, Serefoglou Z, Yapijakis C, Nkenke E, Vassiliou S, Spyridonidou S, Vylliotis A, Nixon AM, Neukam FW, Patsouris E. Anticancer Res. 2007 Jul-Aug;27(4B):2449-51.

48. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E. Am J Hematol. 2007 Nov;82(11):1010-2.

49. Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis. Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, Nkenke E, Vylliotis A, Papakosta V, Lazaris A, Patsouris E. J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):185-90.

50. Diabetes alters expression of p53 and c-myc in different stages of oral oncogenesis. Vairaktaris E, Kalokerinos G, Goutzanis L, Spyridonidou S, Vassiliou S, Derka S, Nkenke E, Yapijakis C, Vylliotis A, Lazaris A, Patsouris E. Anticancer Res. 2007 May-Jun;27(3B):1465-73.

51. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, Spyridonidou S, Vorris E, Neukam F, Patsouris E. J Cancer Res Clin Oncol. 2007 Oct;133(10):787-91.

52. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, Vylliotis A, Yapijakis C, Neukam FW, Patsouris E. Eur J Surg Oncol. 2008 Apr;34(4):450-5.

53. Loss of tumour suppressor p16 expression in initial stages of oral oncogenesis. Vairaktaris E, Yapijakis C, Psyrri A, Spyridonidou S, Yannopoulos A, Lazaris A, Vassiliou S, Ferekidis E, Vylliotis A, Nkenke E, Patsouris E. Anticancer Res. 2007 Mar-Apr;27(2):979-84.

54. Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Vairaktaris E, Yannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Critselis E, Avgoustidis D, Yapijakis C, Neukam FW, Patsouris E. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Dec;104(6):796-802.

55. Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, Ragos V, Vylliotis A, Spyridonidou S, Tsigris C, Yannopoulos A, Tesseromatis C, Neukam FW, Patsouris E. Anticancer Res. 2007 Jan-Feb;27(1A):459-64.

56. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW, Patsouris E. Oncol Rep. 2007 Apr;17(4):963-8.

57. FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Vairaktaris E, Ragos V, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Yannopoulos A, Spyridonidou S, Vylliotis A, Papakosta V, Loukeri S, Lazaris A, Tesseromatis C, Tsigris C, Patsouris E. Anticancer Res. 2006 Nov-Dec;26(6B):4217-21.

58. Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW, Patsouris E. Int J Biol Markers. 2006 Oct-Dec;21(4):246-50.

59. The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Wiltfang J, Avgoustidis D, Critselis E, Neukam FW, Patsouris E. Eur J Surg Oncol. 2007 May;33(4):504-7.

60. Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis. Vairaktaris E, Papageorgiou G, Derka S, Moulavassili P, Nkenke E, Kessler P, Vassiliou S, Papakosta V, Spyridonidou S, Vylliotis A, Lazaris AC, Anagnostopoulou S, Mourouzis C, Yapijakis C, Patsouris E. J Cancer Res Clin Oncol. 2007 Apr;133(4):227-33.

61. The co-expression of c-myc and p53 increases and reaches a plateau early in oral oncogenesis. Papakosta V, Vairaktaris E, Vylliotis A, Derka S, Nkenke E, Vassiliou S, Lazaris A, Mourouzis C, Rallis G, Spyridonidou S, Anagnostopoulou S, Perrea D, Donta I, Yapijakis C, Patsouris E. Anticancer Res. 2006 Jul-Aug;26(4B):2957-62.

62. Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway. Goutzanis L, Vairaktaris E, Yapijakis C, Kavantzas N, Nkenke E, Derka S, Vassiliou S, Acil Y, Kessler P, Stavrianeas N, Perrea D, Donta I, Skandalakis P, Patsouris E. Oral Oncol. 2007 Feb;43(2):165-73.

63. Immunological and molecular detection of human immunodeficiency virus in saliva, and comparison with blood testing. Yapijakis C, Panis V, Koufaliotis N, Yfanti G, Karachalios S, Roumeliotou A, Mantzavinos Z. Eur J Oral Sci. 2006 Jun;114(3):175-9.

64. Ancient typhoid epidemic reveals possible ancestral strain of Salmonella enterica serovar Typhi. Papagrigorakis MJ, Synodinos PN, Yapijakis C. Infect Genet Evol. 2007 Jan;7(1):126-7.

65. Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P, Neukam FW. Oral Oncol. 2006 Oct;42(9):888-92.

66. Insufficient phylogenetic analysis may not exclude candidacy of typhoid fever as a probable cause of the Plague of Athens (reply to Shapiro et al.). Papagrigorakis MJ, Yapijakis C, Synodinos PN, Baziotopoulou-Valavani E. Int J Infectious Dis 10: 335-336, 2006.

67. Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, Springer I, Nkenke E, Kessler P, Neukam FW. Eur J Surg Oncol. 2006 May;32(4):455-7.

68. Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Derka S, Vairaktaris E, Papakosta V, Vassiliou S, Acil Y, Vylliotis A, Spyridonidou S, Lazaris AC, Mourouzis C, Kokkori A, Moulavasili P, Perrea D, Donta I, Yapijakis C, Patsouris E. Oral Oncol. 2006 May;42(5):540-50.

69. DNA examination of ancient dental pulp incriminates typhoid fever as a probable cause of the Plague of Athens. Papagrigorakis MJ, Yapijakis C, Synodinos PN, Baziotopoulou-Valavani E. Int J Infect Dis. 2006 May;10(3):206-14.

70. Real-time PCR analysis of trinucleotide repeat allele expansions in the androgen receptor gene. Chatzikyriakidou A, Yapijakis C, Sofikitis N, Vassilopoulos D, Georgiou I. Mol Diagn. 2005;9(4):217-9.

71. Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. Vairaktaris E, Yapijakis C, Kessler P, Vylliotis A, Ries J, Wiltfang J, Vassiliou S, Derka S, Neukam FW. J Cancer Res Clin Oncol. 2006 Apr;132(4):219-22.

72. Are factor V and prothrombin mutations associated with increased risk of oral cancer? Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Derka S, Vasiliou S, Neukam FW. Anticancer Res. 2005 May-Jun;25(3c):2561-5.

73. Salivary gland manifestations of sarcoidosis: report of three cases. Vairaktaris E, Vassiliou S, Yapijakis C, Papakosta V, Kavantzas N, Martis C, Patsouris E. J Oral Maxillofac Surg. 2005 Jul;63(7):1016-21.

74. Use of truncated pyramid representation methodology in three-dimensional reconstruction: an example. Papadimitriou C, Yapijakis C, Davaki P. J Microsc. 2004 Apr;214:70-5.

75. Prenatal testing for Huntington’s disease: a European collaborative study. Simpson SA, Zoeteweij MW, Nys K, Harper P, Dürr A, Jacopini G, Yapijakis C, Evers-Kiebooms G. Eur J Hum Genet. 2002 Nov;10(11):689-93.

76. Clinical and genetic heterogeneity in benign hereditary chorea. Breedveld GJ, Percy AK, MacDonald ME, de Vries BB, Yapijakis C, Dure LS, Ippel EF, Sandkuijl LA, Heutink P, Arts WF. Neurology. 2002 Aug 27;59(4):579-84.

77. Thyroid gland neurofibroma in a NF1 patient. Anagnostouli M, Piperingos G, Yapijakis C, Gourtzelidis P, Balafouta S, Zournas C, Vassilopoulos D, Koutras D, Papageorgiou C. Acta Neurol Scand. 2002 Jul;106(1):58-61.

78. Association of oestrogen receptor alpha polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. Kukuvitis A, Georgiou I, Bouba I, Tsirka A, Giannouli CH, Yapijakis C, Tarlatzis B, Bontis J, Lolis D, Sofikitis N, Papadimas J. Int J Androl. 2002 Jun;25(3):149-52.

79. A simple and effective approach for detecting maternal cell contamination in molecular prenatal diagnosis. Antoniadi T, Yapijakis C, Kaminopetros P, Makatsoris C, Velissariou V, Vassilopoulos D, Petersen MB. Prenat Diagn. 2002 May;22(5):425-9.

80. Predictive DNA-testing for Huntington’s disease and reproductive decision making: a European collaborative study. Evers-Kiebooms G, Nys K, Harper P, Zoeteweij M, Dürr A, Jacopini G, Yapijakis C, Simpson S. Eur J Hum Genet. 2002 Mar;10(3):167-76.

81. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: A European collaborative study. Nelis E, van Broeckhoven C and coauthors (including Yapijakis C, Vassilopoulos D). Eur J Hum Genet 4: 25-33, 1996.

82. Hereditary neuropathy with liability to pressure palsies: the same molecular defect can result in diverse clinical presentation. Andreadou E, Yapijakis C, Paraskevas GP, Stavropoulos P, Karadimas C, Zis VP, Davaki P, Karandreas N, Rentzos M, Tsakanikas C, Vassilopoulos D, Papageorgiou C. J Neurol. 1996 Mar;243(3):225-30.

83. Prenatal diagnosis of X-linked spinal and bulbar muscular atrophy in a Greek family. Yapijakis C, Kapaki E, Boussiou M, Vassilopoulos D, Papageorgiou C. Prenat Diagn. 1996 Mar;16(3):262-5.

84. Status report on molecular genetic studies of affective disorders. Aschauer HN et al. (including Stefanis CN, Papadimitriou GN, Dikeos DG, Yapijakis C, Vassilopoulos D). Psychiatric Genet 5: 9-21, 1995.

85. Exclusion mapping of the benign hereditary chorea gene from the Huntington’s disease locus: report of a family. Yapijakis C, Kapaki E, Zournas C, Rentzos M, Loukopoulos D, Papageorgiou C. Clin Genet. 1995 Mar;47(3):133-8.

86. Linkage disequilibrium between the expanded (CAG)n repeat and an allele of the adjacent (CCG)n repeat in Huntington’s disease patients of Greek origin. Yapijakis C, Vassilopoulos D, Tzagournisakis M, Maris T, Fesdjian C, Papageorgiou C, Plaitakis A. Eur J Hum Genet. 1995;3(4):228-34.

87. Isolation of temperature-sensitive mutants of 16 S rRNA in Escherichia coli. Triman K, Becker E, Dammel C, Katz J, Mori H, Douthwaite S, Yapijakis C, Yoast S, Noller HF. J Mol Biol. 1989 Oct 20;209(4):645-53.